Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Dan Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6709-4932; OpenAlex author ID A5052964199. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2019: 1 paper · 2020: 4 papers · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 12

  1. Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies. Last author DOI 10.3389/fimmu.2024.1326556↗
  2. Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report. Co-author DOI 10.1186/s12883-023-03140-7↗
  3. Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a s… Last author DOI 10.1136/bmjopen-2021-050558↗
  4. A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study. Last author DOI 10.1177/10732748221141233↗
  5. Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarc… Last author DOI 10.1186/s12885-021-08275-9↗
  6. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12967-021-02972-6↗
  7. Durable Response of Induction Sequential Chemotherapy Combined With Nimotuzumab and Consolidative Carbon Ion Radiotherapy With Non-V600 BRAF Mutation Locally A… Last author DOI 10.21203/rs.3.rs-809969/v1↗
  8. Alteration of Transforming Growth Factor β Signaling Pathway Predicts Worse Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001522↗
  9. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for … Last author DOI 10.1186/s12885-020-07126-3↗
  10. An Unexpected Case Report of Adrenal Lymphangioma: Mimicking Metastatic Tumor on Imaging in a Patient With Pancreatic Cancer. Co-author DOI 10.3389/fendo.2020.610744↗
  11. Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Ad… Last author DOI 10.3389/fimmu.2020.01127↗
  12. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, an… Last author DOI 10.1186/s13014-019-1330-0↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ke Cheng · 5 shared papers, 2020–2023 · strength 0.76
  2. Chen Chang · 3 shared papers, 2021–2022 · strength 0.52
  3. Yi Cheng · 4 shared papers, 2020–2022 · strength 0.51
  4. Wanrui Lv · 2 shared papers, 2022–2023 · strength 0.44
  5. Lin Shui · 3 shared papers, 2020–2021 · strength 0.34
  6. Qiancheng Hu · 2 shared papers, 2019–2022 · strength 0.32
  7. Xiaoying Li · 1 shared paper, 2024 · strength 0.26
  8. Bole Tian · 2 shared papers, 2020–2021 · strength 0.24
  9. Xi Chen · 1 shared paper, 2023 · strength 0.24
  10. Jianping He · 1 shared paper, 2023 · strength 0.24
  11. Shuangshuang Li · 2 shared papers, 2020–2021 · strength 0.23
  12. Li Mao · 2 shared papers, 2020–2021 · strength 0.23
  13. Ang Li · 2 shared papers, 2020–2021 · strength 0.23
  14. Xin Wang · 1 shared paper, 2022 · strength 0.20
  15. Bing Peng · 1 shared paper, 2022 · strength 0.16
  16. Zheng Wang · 1 shared paper, 2021 · strength 0.13
  17. Shang Wan · 1 shared paper, 2020 · strength 0.13
  18. Bin Song Md · 1 shared paper, 2020 · strength 0.13
  19. Heli Gao · 1 shared paper, 2021 · strength 0.12
  20. Ning An · 1 shared paper, 2021 · strength 0.12
  21. Peng Cao · 1 shared paper, 2019 · strength 0.11
  22. Xubao Liu · 1 shared paper, 2020 · strength 0.11
  23. Yu Mou · 1 shared paper, 2020 · strength 0.11
  24. Bole Tian · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.